List view / Grid view
8 August 2013 | By Teva Pharmaceutical Industries Ltd
TEVA announced that the European Commission has granted marketing authorization for Lonquex® (lipegfilgrastim)...
8 August 2013 | By Johnson & Johnson
Janssen announced that the European Commission has approved the use of VELCADE® (bortezomib)...
8 August 2013 | By Novartis
"At Novartis, we believe that everyone should have access to early screening programs and innovative therapies..."
8 August 2013 | By GlaxoSmithKline
GlaxoSmithKline announced the launch of Action Potential Venture Capital (APVC) Limited...
7 August 2013 | By Novartis
Everolimus did not show survival benefit for patients with advanced hepatocellular carcinoma (HCC) after progression on or intolerance to sorafinib...
6 August 2013 | By Financial Times
3 – 4 December 2013, The InterContinental Park Lane, London...
6 August 2013 | By GlaxoSmithKline
“This EU filing, the third for pazopanib in less than five years, confirms GSK’s commitment to deliver our oncology pipeline..."
5 August 2013 | By Sanofi
Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide...
5 August 2013 | By Roche
The Medicines Patent Pool and Roche announce an agreement...
2 August 2013 | By GlaxoSmithKline
GlaxoSmithKline announced that the US Prescription Drug User Fee Act (PDUFA) goal date for albiglutide has been extended by three months...
1 August 2013 | By Boehringer Ingelheim
Data from the LUX-Lung clinical trial programme...
1 August 2013 | By Novartis
Novartis announced that the US FDA approved Menveo®...
31 July 2013 | By Sanofi
Sanofi announced the appointment of two new members to the Executive Committee, effective September 1st, 2013...
31 July 2013 | By AstraZeneca
Collaboration to include US, China and selected other markets...
31 July 2013 | By Boehringer Ingelheim
Boehringer Ingelheim (BI) and Eli Lilly and Company today announced enrollment of the first patient into a cardiovascular and renal outcomes trial for linagliptin (Trajenta®). The CARMELINA1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with Type 2 Diabetes mellitus at high vascular risk) trial will investigate the…
